Further data on beta-blockers and cancer risk: Observational study and meta-analysis of randomized clinical trials

Current Medical Research and Opinion

Volumn 29, Issue 4, 2013, Pages 369-378

  Monami, Matteo ^a   Filippi, Luca ^b   Ungar, Andrea ^a   Sgrilli, Federica ^a   Antenore, Alessandro ^a   Dicembrini, Ilaria ^c   Bagnoli, Paola ^d   Marchionni, Niccolò ^a   Rotella, Carlo Maria ^c   Mannucci, Edoardo ^d  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c Careggi Teaching Hospital   (Italy)

^d UNIVERSITY OF PISA   (Italy)

Author keywords

Beta blockers; Cancer; Case; Control study; Meta analysis

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HEMOGLOBIN A1C; HUMAN INSULIN; HYDROCHLOROTHIAZIDE; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; LOSARTAN; METFORMIN; NEBIVOLOL; PLACEBO; PROPRANOLOL; QUINAPRIL; THIAZOLIDINE DERIVATIVE; VERAPAMIL;

ADULT; ALCOHOL CONSUMPTION; ANTIHYPERTENSIVE THERAPY; ARTICLE; BODY MASS; CANCER RISK; CEREBROVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEATH; DIABETIC FOOT; DIABETIC PATIENT; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; INSULIN TREATMENT; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; NEOPLASM; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; RETINOPATHY; SMOKING;

ADRENERGIC BETA-ANTAGONISTS; AGED; ATENOLOL; BENZOPYRANS; BISOPROLOL; CARBAZOLES; DIABETES MELLITUS; ETHANOLAMINES; FEMALE; HUMANS; INSULIN; INSULIN, LONG-ACTING; MALE; METFORMIN; MYOCARDIAL ISCHEMIA; NEOPLASMS; PROPANOLAMINES; RISK;

EID: 84875190429     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.772505     Document Type: Article

References (73)

1. Sood AK, Bhatty R, Kamat AA, et al. Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res 2006;12:369-75
2. Lee JW, Shahzad MM, Lin YG, et al. Surgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res 2009;15:2695-702
3. Thaker PH, Han LY, Kamat AA, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 2006;12:939-44
4. Guo K, Ma Q, Wang L, et al. Norepinephrine-induced invasion by pancreatic cancer cells is inhibited by propranolol. Oncol Rep 2009;22:825-30
5. Schuller HM, Porter B, Riechert A. Beta-adrenergic modulation of NNKinduced lung carcinogenesis in hamsters. J Cancer Res Clin Oncol 2000;126:624-30
6. Sloan EK, Priceman SJ, Cox BF, et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res 2010;70:7042-52
7. Palm D, Lang K, Niggemann B, et al. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int J Cancer 2006;118:2744-9
8. Masur K, Niggemann B, Zanker KS, et al. Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res 2001;61:2866-9
9. Fitzgerald PJ. Is norepinephrine an etiological factor in some types of cancer? Int J Cancer 2009;124:257-63
10. Entschladen F, Drell 4th TL, Lang K, et al. Tumour-cell migration, invasion, and metastasis: navigation by neurotransmitters. Lancet Oncol 2004;5:254-8
11. Drell 4th TL, Joseph J, Lang K, et al. Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat 2003;80:63-70
12. Lin X, Luo K, Lv Z, et al. Beta-adrenoceptor action on pancreatic cancer cell proliferation and tumor growth in mice. Hepatogastroenterology 2012;59:584-8
13. Lutgendorf SK, Cole S, Costanzo E, et al. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res 2003;9:4514-21
14. Yang EV, Sood AK, Chen M, et al. Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res 2006; 66:10357-64
15. Yang EV, Kim SJ, Donovan EL, et al. Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression. Brain Behav Immun 2009;23:267-75
16. Chakroborty D, Sarkar C, Basu B, et al. Catecholamines regulate tumor angiogenesis. Cancer Res 2009;69:3727-30
17. Park SY, Kang JH, Jeong KJ, et al. Norepinephrine induces VEGF expression and angiogenesis by a hypoxia-inducible factor-1a protein-dependent mechanism. Int J Cancer 2011;128:2306-16
18. Entschladen F, Drell 4th TL, Lang K, et al. Neurotransmitters and chemokines regulate tumor cell migration: potential for a new pharmacological approach to inhibit invasion and metastasis development. Curr Pharm Des 2005;11:403-11
19. Chalothorn D, Zhang H, Clayton JA, et al. Catecholamines augment collateral vessel growth and angiogenesis in hindlimb ischemia. Am J Physiol Heart Circ Physiol 2005;289:H947-59
20. Liao X, Che X, Zhao W, et al. The adrenoceptor antagonist, propranolol, induces human gastric cancer cell apoptosis and cell cycle arrest via inhibiting nuclear factor kB signaling. Oncol Rep 2010;24:1669-76
21. Zhang D, Ma Q, Shen S, et al. Inhibition of pancreatic cancer cell proliferation by propranolol occurs through apoptosis induction: the study of beta-adrenoceptor antagonist's anticancer effect in pancreatic cancer cell. Pancreas 2009;38:94-100
22. Al-Wadei HA, Al-Wadei MH, Schuller HM. Prevention of pancreatic cancer by the beta-blocker propranolol. Anticancer Drugs 2009;20:477-82
23. Powe DG, Voss MJ, Zanker KS, et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 2010;1:628-38
24. Diaz ES, Karlan BY, Li AJ. Impact of beta blockers on epithelial ovarian cancer survival. Gynecol Oncol 2012;127:375-8
25. Grytli HH, Fagerland MW, Fossa SD, et al. Use of blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy. Prostate 2013;73(3):250-60. published online 20 July 2012, doi:10.1002/pros.22564
26. De Giorgi V, Grazzini M, Gandini S, et al. Treatment with {beta}-blockers and reduced disease progression in patients with thick melanoma. Arch Intern Med 2011;171:779-81
27. Lemeshow S, Sørensen HT, Phillips G, et al. Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study. Cancer Epidemiol Biomarkers Prev 2011;20:2273-9
28. Shah SM, Carey IM, Owen CG, et al. Does adrenoceptor blocker therapy improve cancer survival? Findings from a population-based retrospective cohort study. Br J Clin Pharmacol 2011;72:157-61
29. Algazi M, Plu-Bureau G, Flahault A, et al. Could treatments with beta-blockers be associated with a reduction in cancer risk? Rev Epidemiol Sante Publique 2004;52:53-65
30. Perron L, Bairati I, Harel F, et al. Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control 2004;15:535-41
31. Nkontchou G, Aout M, Mahmoudi A, et al. Effect of long-term propranolol treatment on hepatocellular carcinoma incidence in patients with HCV-associated cirrhosis. Cancer Prev Res (Phila) 2012;5:1007-14
32. Barron TI, Connolly RM, Sharp L, et al. Beta blockers and breast cancer mortality: a population-based study. J Clin Oncol 2011;29:2635-44
33. Ganz PA, Habel LA, Weltzien EK, et al. Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Res Treat 2011;129:549-56
34. Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 2011;29:2645-52
35. Friedman GD, Udaltsova N, Chan J, et al. Screening pharmaceuticals for possible carcinogenic effects: initial positive results for drugs not previously screened. Cancer Causes Control 2009;20:1821-35
36. Fryzek JP, Poulsen AH, Lipworth L, et al. A cohort study of antihypertensive medication use and breast cancer among Danish women. Breast Cancer Res Treat 2006;97:231-6
37. Jansen L, Below J, Chang-Claude J, et al. Beta blocker use and colorectal cancer risk: population-based case-control study. Cancer 2012; 118:3911-19
38. Coleman CI, Baker WL, Kluger J, et al. Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials. J Hypertens 2008;26:622-9
39. Bangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol 2011;12:65-82
40. Black HR, Elliott WJ, Grandits G, et al.; CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003;289:2073-82
41. Lindholm LH, Hansson L, Ekbom T, et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. J Hypertens 2000;18:1671-5
42. Mannucci E, Monami M, Balzi D, et al. Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 2010;33:1997-2003
43. Chalmers J, MacMahon S, Mancia G, et al. 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization. Clin Exp Hypertens 1999;21:1009-60
44. Charlson M, Szatrowski TP, Peterson J, et al. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47:1245-51
45. Moher D, Liberati A, Tetzlaff J, et al.; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006-12
46. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101
47. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34
48. Miller AB, Reichek N, St John Sutton M, et al. Importance of blood pressure control in left ventricular mass regression. J Am Soc Hypertens 2010;4:302-10
49. NCT00744237. Available at: http://clinicaltrials.gov/ct2/show/NCT00744237 [Last accessed 6 June 2012]
50. Nielsen FS, Rossing P, Gall MA, et al. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1997;46:1182-8
51. Veterans Administration Cooperative Study Group. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. II. Results of long-term therapy. Veterans Administration Cooperative Study Group on Antihypertensive Agents JAMA 1982;248:2004-11
52. Suwelack B, Kobelt V, Erfmann M, et al. Long-term follow-up of ACE-inhibitor versus beta-blocker treatment and their effects on blood pressure and kidney function in renal transplant recipients. Transpl Int 2003;16:313-20
53. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J (Clin Res Ed) 1986;293:1145-51
54. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al.; INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805-16
55. Lindholm LH, Ibsen H, Dahlof B, et al.; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-10
56. Gupta AK, Dahlof B, Dobson J, et al.; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. Diabetes Care 2008;31:982-8
57. Nadim MK, Dua R, Campese VM. Antihypertensive drugs and the kidney. Curr Cardiol Rep 2004;6:403-8
58. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009;361:40-51
59. Ungar A, Di Serio C, Lambertucci L, et al. Calcium channel blockers and nephroprotection. Aging Clin Exp Res 2005;17(4 Suppl):31-9
60. Wenzel RR. Renal protection in hypertensive patients: selection of antihypertensive therapy. Drugs 2005;65(Suppl 2):29-39
61. Monami M, Colombi C, Balzi D, et al. Metformin and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 2011;34:129-31
62. Shang ZJ, Liu K, Liang de F. Expression of beta2-adrenergic receptor in oral squamous cell carcinoma. J Oral Pathol Med 2009;38:371-6
63. Pearce PC, Hawkey CM, Symons C, et al. The importance of membrane stabilization in protecting the developing rat myocardium from the actions of triac. Am J Cardiovasc Pathol 1988;2:173-9
64. Mansuy P, Mougenot N, Ramirez-Gil JF, et al. Effects of prolonged propranolol treatment on left ventricular remodeling and oxidative stress after myocardial infarction in rats. J Cardiovasc Pharmacol 2000; 35:806-13
65. Fitzgerald PJ. Testing whether drugs that weaken norepinephrine signaling prevent or treat various types of cancer. Clin Epidemiol 2010;2:1-3
66. Shan T, Ma Q, Zhang D, et al. 2-adrenoceptor blocker synergizes with gemcitabine to inhibit the proliferation of pancreatic cancer cells via apoptosis induction. Eur J Pharmacol 2011;665:1-7
67. Wolter NE, Wolter JK, Enepekides DJ, et al. Propranolol as a novel adjunctive treatment for head and neck squamous cell carcinoma. J Otolaryngol Head Neck Surg 2012;41:334-44
68. Pasquier E, Ciccolini J, Carre M, et al. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget 2011;2:797-809
69. Beta-adrenergic blockers and breast cancer. Med Lett Drugs Ther 2012;54:6-7
70. Leaute-Labreze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008;358:2649-51
71. Ristori C, Filippi L, Dal Monte M, et al. Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade. Invest Ophthalmol Vis Sci 2011; 52:155-70
72. Martini D, Monte MD, Ristori C, et al. Antiangiogenic effects of -(2)-adrenergic receptor blockade in a mouse model of oxygen-induced retinopathy. J Neurochem 2011;119:1317-29
73. Filippi L, Cavallaro G, Fiorini P, et al. Study protocol: safety and efficacy of propranolol in newborns with Retinopathy of Prematurity (PROP-ROP): ISRCTN18523491. BMC Pediatr 2010;10:83